Back to top

Strength Seen in Cellectis S.A. (CLLS): Stock Soars 8.95%
July 17, 2017

Read MoreHide Full Article

Cellectis S.A. (CLLS - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 25.8% in the past one-month time frame.

The upside is likely to have taken place after the company announced that its wholly owned subsidiary, Calyxt, Inc., has started the process for an IPO (initial public offering) and filed relevant papers with the US Securities and Exchange Commission.

The company has seen two positive estimate revisions in the past one month, while its Zacks Consensus Estimate for the current quarter has also moved higher over the same time frame, suggesting that more solid trading could be ahead for Cellectis. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Cellectis currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.

Cellectis S.A. Price and Consensus

Another stock worth considering in the Utility - Electric Powerindustry is Atlantica Yield PLC which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Is CLLS going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively. 

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Cellectis S.A. (CLLS) - free report >>


More from Zacks Tale of the Tape

You May Like